Eribulin Mesylate Injection (Halaven)

Elliott, William T.; Chan, James
January 2011
Internal Medicine Alert;1/29/2011, Vol. 33 Issue 2, p14
The article examines the efficacy of eribulin mesylate, a halichondrins marketed by Eisai Inc. as Halaven, as chemotherapeutic agent for the treatment of metastatic breast cancer.


Related Articles

  • Eisai Inc. Receives J-Code from CMS for Halaven(r) (eribulin mesylate) Injection.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article reports that Eisai Inc. has received permanent Healthcare Common Procedure Coding System (HCPCS) J-code from the U.S. Centers for Medicare and Medicaid Services (CMS). It is mentioned that the code is assigned for Halaven injection, drug which is used to treat metastatic breast...

  • Breast cancer: The search for the cure continues. Magill-Lewis, Jillene // Drug Topics;5/5/2003 Supplement, Vol. 147 Issue 9, p19S 

    Discusses the continuous search for the treatment of breast cancer. Epidemiology of the disease in the U.S.; Drugs used to treat breast cancer; Efforts of researchers to make current drugs more effective and less toxic; Major concern on metastatic breast cancer.

  • Focus on docetaxel: A new antineoplastic agent approved by the FDA for the treatment of locally... Martin, William R. // Formulary;Oct96, Vol. 31 Issue 10, p891 

    Evaluates the effectiveness of docetaxel, an antineoplastic agent approved by the Food and Drug Administration for the treatment of locally advanced or metastatic breast cancer. Chemistry; Pharmacology; Pharmacokinetics; Result of clinical trials; Formulary considerations; Drug interactions;...

  • Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. // British Journal of Cancer;7/1/2002, Vol. 87 Issue 1, p21 

    Besides cytotoxicity, taxanes induce other biological effects, especially in the immune system. Taxanes have demonstrated immunostimulatory effects against neoplasms, supporting the idea that these agents suppress cancer through several mechanisms and not solely through inhibiting cell division....

  • Ixabepilone Injection (Ixempra). Elliott, William T.; Chan, James // Internal Medicine Alert;12/15/2007, Vol. 29 Issue 23, p181 

    The FDA has approved a new drug for the treatment of advanced breast cancer. Ixabepilone is a microtubule inhibitor in the class of epothilones. The drug was approved by priority review and is manufactured by Baxter Oncology GmBH in Germany and marketed by Bristol-Myers Squibb as Ixempra.â„¢...

  • Breast cancer patients now have a new option. Cerrato, Paul L. // RN;May96, Vol. 59 Issue 5, p77 

    Reports that the antineoplastic agent goserelin (Zoladex) could be used in the treatment of breast cancer. How the drug works; Details on the side effects of the drug.

  • Arimidex Results Expand Anticancer Class. Krause, Carey // Chemical Market Reporter;9/16/2002, Vol. 262 Issue 9, p14 

    Reports the approval of AstraZenica Plc's supplemental drug application for Arimidex as an adjuvant treatment of postmenopausal breast cancer. Risk reduction for breast cancer recurrence; Replacement of Nolvadex sales; Arimidex sales in 2002.

  • Data does not support sunitinib/capecitabine combo for advanced breast cancer.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p20 

    The article discusses a phase 3 clinical trial which examines the effectiveness of sunitinib plus capecitabine for treating advanced breast cancer.

  • New breast cancer drugs on the way. Gebhart, Fred // Drug Topics;7/8/96, Vol. 140 Issue 13, p71 

    Reports on the development of anticancer drugs for advanced-state breast cancer patients in the United States. Topoisomerase I inhibitors; Results from clinical trials; Effectiveness.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics